Neuroprotective potential of peroxisome proliferator activated receptor-α agonist in cognitive impairment in Parkinson's disease: Behavioral, biochemical, and PBPK profile

PPAR Research

Volumn 2014, Issue , 2014, Pages

  Uppalapati, Dedeepya ^a   Das, Nihar R ^a   Gangwal, Rahul P ^a   Damre, Mangesh V ^a   Sangamwar, Abhay T ^a   Sharma, Shyam S ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BIOCHEMISTRY; COGNITIVE DEFECT; CONFUSION; CONTROLLED STUDY; DNA FRAGMENTATION; FEMALE; IMMUNOHISTOCHEMISTRY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; RAT;

EID: 84896269947     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2014/753587     Document Type: Article

References (44)

1. Tardiff D. F., Lindquist S., Phenotypic screens for compounds that target the cellular pathologies underlying Parkinson's disease. Drug Discovery Today: Technologies 2013 10 1 e121 e128 2-s2.0-84858952815 10.1016/j.ddtec.2012.02.003
2. Hwang O., Role of oxidative stress in Parkinson's disease. Experimental Neurobiology 2013 22 1 11 17 10.5607/en.2013.22.1.11
3. Taylor J. M., Main B. S., Crack P. J., Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochemistry International 2013 62 5 803 819 10.1016/j.neuint.2012.12.016
4. Exner N., Lutz A. K., Haass C., Winklhofer K. F., Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO Journal 2012 31 14 3038 3062 10.1038/emboj.2012.170
5. Blandini F., An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. Functional Neurology 2010 25 2 65 71 2-s2.0-77957664714
6. Gundersen V., Protein aggregation in Parkinson's disease. Acta Neurologica Scandinavica 2010 122 190 82 87 2-s2.0-77953176596 10.1111/j.1600-0404.2010.01382.x
7. Jankovic J., Parkinson's disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery and Psychiatry 2008 79 4 368 376 2-s2.0-41149163183 10.1136/jnnp.2007.131045 (Pubitemid 351441488)
8. Emre M., Dementia associated with Parkinson's disease. The Lancet Neurology 2003 2 4 229 237 2-s2.0-0042970162 10.1016/S1474-4422(03)00351-X (Pubitemid 37443310)
9. Aarsland D., Andersen K., Larsen J. P., Lolk A., Nielsen H., Kragh-Sørensen P., Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001 56 6 730 736 2-s2.0-0035957311 (Pubitemid 32240091)
10. Reid W. G. J., Hely M. A., Morris J. G. L., Loy C., Halliday G. M., Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). Journal of Neurology, Neurosurgery and Psychiatry 2011 82 9 1033 1037 2-s2.0-80051552956 10.1136/jnnp.2010.232678
11. Burston J., Kendall D., Peroxisome proliferator-activated receptors and inflammation. Endocannabinoids 2013 Springer 221 233
12. Berger J., Moller D. E., The mechanisms of action of PPARs. Annual Review of Medicine 2002 53 1 409 435 2-s2.0-0036183630 10.1146/annurev.med.53.082901. 104018 (Pubitemid 34177889)
13. Landreth G., Therapeutic use of agonists of the nuclear receptor PPAR γ in Alzheimer's disease. Current Alzheimer Research 2007 4 2 159 164 2-s2.0-34147102288 10.2174/156720507780362092 (Pubitemid 46557505)
14. Ouk T., Potey C., Gautier S., Bastide M., Deplanque D., Staels B., Duriez P., Leys D., Bordet R., PPARs: a potential target for a disease-modifying strategy in stroke. Current Drug Targets 2013 14 7 752 767 10.2174/ 1389450111314070005
15. Jin J., Albertz J., Guo Z., Peng Q., Rudow G., Troncoso J. C., Ross C. A., Duan W., Neuroprotective effects of PPAR γ agonist rosiglitazone in N17182Q mouse model of Huntington's disease. Journal of Neurochemistry 2013 125 3 410 419 10.1111/jnc.12190
16. Storer P. D., Xu J., Chavis J., Drew P. D., Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. Journal of Neuroimmunology 2005 161 1-2 113 122 2-s2.0-14844282813 10.1016/j.jneuroim.2004. 12.015 (Pubitemid 40340879)
17. Breidert T., Callebert J., Heneka M. T., Landreth G., Launay J. M., Hirsch E. C., Protective action of the peroxisome proliferator-activated receptor- γ agonist pioglitazone in a mouse model of Parkinson's disease. Journal of Neurochemistry 2002 82 3 615 624 2-s2.0-0036326074 10.1046/j.1471-4159.2002.00990.x (Pubitemid 34831499)
18. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., Carta A. R., PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. European Journal of Neuroscience 2009 29 5 954 963 2-s2.0-61449237400 10.1111/j.1460-9568.2009.06657.x
19. Martin H. L., Mounsey R. B., Sathe K., Mustafa S., Nelson M. C., Evans R. M., Teismann P., A PPAR γ agonist provides neuroprotection in the MPTP model of Parkinson's Disease. Neuroscience 2013 240 100 191 203 10.1016/j.neuroscience.2013.02.058
20. Kreisler A., Gelé P., Wiart J.-F., Lhermitte M., Destée A., Bordet R., Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Research 2007 1135 1 77 84 2-s2.0-33846641782 10.1016/j.brainres.2006.12.011 (Pubitemid 46176827)
21. Kumar P., Kaundal R. K., More S., Sharma S. S., Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. Behavioural Brain Research 2009 197 2 398 403 2-s2.0-58149347303 10.1016/j.bbr.2008.10.010
22. Da Cunha C., Gevaerd M. S., Vital M. A. B. F., Miyoshi E., Andreatini R., Silveira R., Takahashi R. N., Canteras N. S., Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behavioural Brain Research 2001 124 1 9 18 2-s2.0-0034980098 10.1016/S0166-4328(01)00211-X (Pubitemid 32567554)
23. Sonkusare S., Srinivasan K., Kaul C., Ramarao P., Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. Life Sciences 2005 77 1 1 14 2-s2.0-17444398214 10.1016/j.lfs.2004.10.036 (Pubitemid 40546372)
24. Pathan A. R., Viswanad B., Sonkusare S. K., Ramarao P., Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sciences 2006 79 23 2209 2216 2-s2.0-33750454798 10.1016/j.lfs.2006.07.018 (Pubitemid 44646475)
25. Vorhees C. V., Williams M. T., Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nature Protocols 2006 1 2 848 858 2-s2.0-33846461062 10.1038/nprot.2006.116
26. Ohkawa H., Ohishi N., Yagi K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry 1979 95 2 351 358 2-s2.0-0018384650 (Pubitemid 9194347)
27. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J., Protein measurement with the folin phenol reagent. The Journal of Biological Chemistry 1951 193 1 265 275 2-s2.0-71849104860
28. Moron M. S., Depierre J. W., Mannervik B., Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochimica et Biophysica Acta 1979 582 1 67 78 2-s2.0-0018327389 (Pubitemid 9065588)
29. Rahman I., Kode A., Biswas S. K., Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nature Protocols 2007 1 6 3159 3165 2-s2.0-34548851693 10.1038/nprot.2006.378
30. Kaundal R. K., Sharma S. S., Ameliorative effects of GW1929, a nonthiazolidinedione PPAR γ agonist, on inflammation and apoptosis in focal cerebral ischemic-reperfusion injury. Current Neurovascular Research 2011 8 3 236 245 2-s2.0-80051528861 10.2174/156720211796558078
31. Kabra D. G., Thiyagarajan M., Kaul C. L., Sharma S. S., Neuroprotective effect of 4-amino-1,8-napthalimide, a poly(ADP ribose) polymerase inhibitor in middle cerebral artery occlusion-induced focal cerebral ischemia in rat. Brain Research Bulletin 2004 62 5 425 433 2-s2.0-1042302101 10.1016/j.brainresbull. 2003.11.001 (Pubitemid 38198329)
32. Thiyagarajan M., Kaul C. L., Sharma S. S., Neuroprotective efficacy and therapeutic time window of peroxynitrite decomposition catalysts in focal cerebral ischemia in rats. British Journal of Pharmacology 2004 142 5 899 911 2-s2.0-3242892582 10.1038/sj.bjp.0705811 (Pubitemid 38998103)
33. Li X., Gu L., Xu Y., Wang Y., Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats. Drug Development and Industrial Pharmacy 2009 35 7 827 833 2-s2.0-70350639421 10.1080/ 03639040802623941
34. Hanafy A., Spahn-Langguth H., Vergnault G., Grenier P., Tubic Grozdanis M., Lenhardt T., Langguth P., Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Advanced Drug Delivery Reviews 2007 59 6 419 426 2-s2.0-34547863131 10.1016/j.addr.2007.04.005 (Pubitemid 47260709)
35. O'Hara T., Dunne A., Butler J., Devane J., A review of methods used to compare dissolution profile data. Pharmaceutical Science and Technology Today 1998 1 5 214 223 2-s2.0-0031864961 10.1016/S1461-5347(98)00053-4 (Pubitemid 28387122)
36. Plaza-Zabala A., Berrendero F., Suarez J., Bermudez-Silva F. J., Fernandez-Espejo E., Serrano A., Pavon F.-J., Parsons L. H., De Fonseca F. R., Maldonado R., Robledo P., Effects of the endogenous PPAR- α agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice. Synapse 2010 64 5 379 389 2-s2.0-73449147663 10.1002/syn.20733
37. Morris R., Developments of a water-maze procedure for studying spatial learning in the rat. Journal of Neuroscience Methods 1984 11 1 47 60 2-s2.0-0021173996 10.1016/0165-0270(84)90007-4 (Pubitemid 14088970)
38. Bhateja D. K., Dhull D. K., Gill A., Sidhu A., Sharma S., Reddy B. V. K., Padi S. S. V., Peroxisome proliferator-activated receptor- α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: Possible neuroprotective mechanisms. European Journal of Pharmacology 2011 674 1 33 43 2-s2.0-82255175318 10.1016/j.ejphar.2011.10.029
39. Zhang Y.-L., Yang J.-Q., Effects of fenofibrate on global cerebral ischemia/reperfusion injury in rats. Chinese Pharmacological Bulletin 2010 26 3 320 324 2-s2.0-77953877077
40. Sharma B., Singh N., Behavioral and biochemical investigations to explore pharmacological potential of PPAR-gamma agonists in vascular dementia of diabetic rats. Pharmacology Biochemistry and Behavior 2011 100 2 320 329 2-s2.0-80054812684 10.1016/j.pbb.2011.08.020
41. Jagatha B., Mythri R. B., Vali S., Bharath M. M. S., Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies. Free Radical Biology and Medicine 2008 44 5 907 917 2-s2.0-39149124146 10.1016/j.freeradbiomed.2007.11.011
42. Sawada M., Imamura K., Nagatsu T., Role of cytokines in inflammatory process in Parkinson's disease. Journal of Neural Transmission, Supplement 2006 70 373 381 2-s2.0-33750373343 (Pubitemid 44622226)
43. Park H. W., Yoo S. J., Park J. H., Protective effects of fenofibrate against the inflammatory cytokines in lipopolysaccharide-induced mice brain tissues. Journal of the Korean Geriatrics Society 2012 16 4 206 216 10.4235/jkgs.2012.16.4.206
44. Broughton B. R. S., Reutens D. C., Sobey C. G., Apoptotic mechanisms after cerebral ischemia. Stroke 2009 40 5 e331 e339 2-s2.0-65549098614 10.1161/STROKEAHA.108.531632